National
Acclaimed gay doctor to be honored at LGBT History Month event
Pediatric cardiologist moved from Louisiana to N.Y. in protest over anti-LGBTQ bills

Dr. Jake Kleinmahon, a gay pediatric cardiologist and pediatric heart transplant specialist, is scheduled to be honored Oct. 1 by the Equality Forum at its annual LGBT History Month Kickoff and Awards Celebration in Philadelphia.
He has been named a recipient of the Equality Forum’s 28th annual International Role Model Award.
Kleinmahon became the subject of national news media coverage in early August when he announced he was leaving the state of Louisiana with his husband and two children and ending his highly acclaimed medical practice in New Orleans after the state legislature passed bills targeting the LGBTQ community.
He had been working since 2018 as the medical director of pediatric heart transplant, heart failure, and ventricular assist device programs at Ochsner Hospital for Children in New Orleans.
Kleinmahon told the Washington Blade his and his family’s decision to leave New Orleans was a difficult one to make. He said it came after the Republican-controlled Louisiana Legislature passed three anti-LGBTQ bills, including a so-called “Don’t Say Gay” bill targeting public schools and a bill banning transition-related medical care for transgender youth.
The state’s Democratic governor, John Bel Edwards, vetoed all three bills. But the legislature overturned his veto of the bill banning transition-related medical care for trans minors beginning Jan. 1, 2024.
Kleinmahon said he and his family moved at the end of August to Long Island, N.Y., after he accepted a new job as director of pediatric heart transplant, heart failure and ventricular assist devices at Cohen Children’s Medical Center in the town of New Hyde Park, which is located along the border of the Borough of Queens in New York City and Nassau County, Long Island.
“The decision to leave is not one that we took lightly at all,” Kleinmahon told the Blade. “And it was not one because I got a better job or other factors,” he said. “The main driver for it was that as we realized where things were going, we were raising our children in a state that was actively trying to make laws against your family,” he said in a phone interview. “And that’s not the type of environment that we want to raise our kids in.”
Kleinmahon said he and his husband Thomas timed their move to Long Island at the end of August so their daughter, who’s seven, could begin school at the start of the school year and their son, who’s four, could begin pre-kindergarten sessions.
“We have been open with our children about why we’re moving because we think it’s important that they carry on this message as well,” said Kleinmahon, who noted that his daughter expressed support for the move.
“We were at the dinner table one night and we were explaining what happened,” Kleinmahon said. “And she goes, you know daddy, we do have a choice, but there is only one good one. And she agreed with our moving to New York.”
Kleinmahon acknowledges that some in New Orleans, which is considered an LGBTQ supportive city in general, questioned his decision to leave on grounds that the two bills that would directly impact him and his family did not become law because the governor’s veto of the two bills were upheld.
“One of the things I’ve heard is that none of these really directly affect a family because the ‘Don’t Say Gay’ bill didn’t go into effect, and my children are not transgender, and I don’t work in a transgender clinic,” he told the Blade.
“But that’s really not the point,” he continued. “The way we think about it as a family, the people who are elected officials that are supposed to take care of the people in their state are casting votes against our families,” he points out. “So, sure, while the laws may not be in effect this year, certainly there’s a push to get them passed. And why would we want to remain in a state that is trying to push forward hateful laws?”
He said he will begin his new job at Cohen Children’s Medical Center on Long Island on Nov. 1.
“They have been incredibly supportive,” Kleinmahon said. “They have actually encouraged me to be open with why we left Louisiana,” he said. “And they have a Pride resource group that’s reached out to me to lend their support,” he said, adding that the hospital and its parent company have been “exceptional in helping us make this transition.”
During his medical practice at Ochsner Hospital for Children in New Orleans, Kleinmahon has been credited with helping to save the lives of many children suffering from heart-related ailments. He said his decision to leave behind his colleagues and patients was difficult.
“Unfortunately, it had ramifications for the kids in Louisiana, which was the hardest part for me,” he said. “And the reason for that is I was one of three pediatric heart transplant cardiologists, and I was the director of the only pediatric heart transplant program in Louisiana.”
He added, “While there are two other fantastic heart transplant cardiologists in Louisiana, the ability to keep a program running that serves an entire state needs a full army of people. And me leaving took 33 percent of that army away.”
He said he was also one of just two pediatric pulmonary hypertension providers in the state, and he just learned that the other provider had also left Louisiana recently. Pulmonary hypertension doctors provide treatment for people with the condition of high blood pressure in their lungs.
Regarding his extensive experience in treating and caring for children with heart disease, Kleinmahon, in response to a question from the Blade, said about 400 children receive heart transplants in the U.S. each year.
While heart transplants for kids are not as frequent as those for adults, he said kids needing a heart transplant and their families “deal with a tremendous amount of stress and medical appointments that really change their life,” including the need to take medication to prevent the body from rejecting a new heart for the rest of the children’s lives.
“My hope as a transplant doctor is that I can get these kids to live as normal a life as possible,” he said.
In addition to presenting its International Role Model Award to Kleinmahon, the Equality Forum was scheduled on Oct. 1 at its LGBT History Month event to present its Frank Kameny Award to Rue Landau, the first LGBTQ Philadelphia City Councilperson. It was also scheduled to present a Special Memorial Tribute to the late Lilli Vincenz, the longtime D.C.-area lesbian activist and filmmaker credited with being a pioneering LGBTQ rights activist beginning in the early 1960s.
“I am beyond humble to receive this award that is really not an award for me but is an award for my family and for families like ours and for people that are going to continue to fight discriminatory policies,” Kleinmahon said.
Blade editor Kevin Naff will present Kleinmahon with the award on Oct. 1 in Philadelphia.
“Dr. Kleinmahon and his family took a brave stand in solidarity with the LGBTQ community and they deserve our gratitude,” Naff said. “I’m excited and honored to present him with the International Role Model Award.”

National
Rural LGBTQ youth face greater hurdles than urban peers: study
Online support is key for many young, queer Americans

A newly released report based on a nationwide U.S. survey of 1,267 LGBTQ young people from the age of 15 to 24 shows that LGBTQ youth living in rural communities face greater hurdles in coping with their sexual orientation or gender identity.
But the report, released by the youth advocacy organizations Hopelab and Born this Way Foundation, also shows that rural LGBTQ youth have benefited significantly by accessing online resources and support services.
The 20-page report, which was released on June 24, is entitled, “Exploring Pride and Support of LGBTQ+ Young People In Rural Communities.”
Here are the key findings of the research as stated in the report:
• Rural LGBTQ+ young people report that their schools (28% vs. 49%), communities (13% vs 35%), and households (47% vs 61%) are less supportive than those of their suburban/urban peers.
• Rural LGBTQ+ young people are significantly more likely than their suburban/urban peers to give (76% vs 70%) and receive (57% vs 51%) support through online friends and communities.
• Rural LGBTQ+ young people are significantly more likely than their suburban/urban peers to meet the threshold for depression (57% vs 45%) and report less flourishing than their suburban/urban counterparts (43% vs 52%).
• Rural LGBTQ+ young people who receive support from those they live with are more likely to be categorized as flourishing (50% vs 35%) and less likely to meet the cutoff for depression (52% vs 63%)than their counterparts with little or no support.
• Despite having less support for LGBTQ+ people in their in-person environments, rural young people report high LGBTQ+ pride at all levels comparable to their suburban/urban peers (85% vs 86%).
“The survey was developed through a collaborative process that included young people in every step, from co-designing survey methods to youth-centered co-distillation support in interpreting results,” a statement released by Hopelab and Born This Way Foundation says.
The statement adds, “The insights directly center on the perspectives of LGBTQ+ young people, ages 15-24, examining how they give and receive support online, their experiences with mental health and well-being, and ways they show kindness and offer support in the face of challenges.”
The report includes a quote from a survey interview of a participant it describes as a white, nonbinary young adult: “Being neurodivergent and Queer in a small town in the South means you’re not very likely to have friends. Finding these people online was my first gateway to being treated like a normal person by my peers. It has greatly shaped who I am today in a positive way. I think I’d still be terribly depressed had I never met them.”
The report concludes by pointing out that despite facing challenges, rural LGBTQ+ young people “demonstrate levels of pride and identity connection that are comparable to their suburban and urban peers.” It adds, “This suggests that even when direct support is lacking, many rural LGBTQ+ young people are still able to find avenues to connect to others similar to them and develop a sense of identity.”
The full report can be accessed at hopelab.org.
U.S. Supreme Court
Nine trans activists arrested outside Supreme Court
Gender Liberation Movement organized demonstration against Skrmetti ruling

On Friday afternoon, nine transgender organizers and allies were arrested on the steps of the U.S. Supreme Court for blocking the street and protesting the recent U.S. v. Skrmetti ruling.
The ruling, decided 6-3 by the conservative majority on Wednesday, upheld Tennessee’s ban on gender-affirming care for minors. The decision will allow states to pass laws restricting gender-affirming care for minors and further minimizes bodily autonomy.
The nine arrested were part of a larger group of more than 30 protesters wearing colors of the trans Pride flag— pink, blue, and white, — standing outside of the nation’s highest court. Organizers unfurled large cloths in pink, blue, and white, shared personal testimonies about how their gender-affirming care was a matter of life and death, released pink and blue smoke, and saw nine trans participants take their hormone replacement therapy.
The protest was led by the Gender Liberation Movement, an organization that “builds direct action, media, and policy interventions centering bodily autonomy, self-determination, the pursuit of fulfillment, and collectivism in the face of gender-based sociopolitical threats.” Among the nine arrested was GLM co-founder Raquel Willis.
Before being arrested, Willis spoke to multiple media outlets, explaining that this decision was an overreach of power by the Supreme Court.
“Gender-affirming care is sacred, powerful, and transformative. With this ruling in U.S. v. Skrmetti, we see just how ignorant the Supreme Court is of the experiences of trans youth and their affirming families,” said Willis. “Everyone deserves the right to holistic healthcare, and trans youth are no different. We will continue to fight for their bodily autonomy, dignity, and self-determination just like previous generations. No court, no law, no government gave us our power, and none can take it away.”
GLM co-founder Eliel Cruz also spoke to media outlets about the Skrmetti ruling, calling it “a historical moment of fascist attacks,” and encouraged the LGBTQ community to “organize and fight back.”
“As a cisgender man, I stand in solidarity with the trans community during these escalating attacks on their safety, well-being, right to exist in this world, and ability to live a future free of violence,” Cruz said. “I’m enraged at the Supreme Court’s decision to uphold a ban on gender-affirming care for youth. My heart hurts for the families and young people who this will negatively impact and harm.”
The Washington Blade reached out to Capitol Police for comment.
A spokesperson said the nine activists were arrested for violating D.C. Code §22-1307 — “Crowding, Obstructing, or Incommoding” — on First Street, N.E., after receiving three warnings.
National
FDA approves new twice-yearly HIV prevention drug
Experts say success could inhibit development of HIV vaccine

The U.S. Food and Drug Administration (FDA) on June 18 approved a newly developed HIV/AIDS prevention drug that only needs to be taken by injection once every six months.
The new drug, lenacapavir, which is being sold under the brand name of Yeztugo by the pharmaceutical company Gilead Sciences that developed it, is being hailed by some AIDS activists as a major advancement in the years-long effort to end the HIV/AIDS epidemic in the U.S. and worldwide.
Although HIV prevention drugs, known as pre-exposure prophylaxis medication or PrEP, have been available since 2012, they initially required taking one or more daily pills. More recently, another injectable PrEP drug was developed that required being administered once every two months.
Experts familiar with the PrEP programs noted that while earlier drugs were highly effective in preventing HIV infection – most were 99 percent effective – they could not be effective if those at risk for HIV who were on the drugs did not adhere to taking their daily pills or injections every two months. Experts also point out that large numbers of people at risk for HIV, especially members of minority communities, are not on PrEP and efforts to reach out to them should be expanded.
“Today marks a monumental advance in HIV prevention,” said Carl Schmid, executive director of the D.C.-based HIV + Hepatitis Policy Institute, in a statement released on the day the FDA announced its approval of lenacapavir.
“Congratulations to the many researchers who spent 19 years to get to today’s approval, backed up by the long-term investment needed to get the drug to market,” he said.
Schmid added, “Long-acting PrEP is now not only effective for up to six months but also improves adherence and will reduce HIV infections – if people are aware of it and payers, including private insurers, cover it without cost-sharing as a preventive service.”
Schmid and others monitoring the nation’s HIV/AIDS programs have warned that proposed large scale cuts in the budget for the U.S. Centers for Disease Control and Prevention by the administration of President Donald Trump could seriously harm HIV prevention programs, including PrEP-related efforts.
“Dismantling these programs means that there will be a weakened public health infrastructure and much less HIV testing, which is needed before a person can take PrEP,” Schmid said in his statement.
“Private insurers and employers must also immediately cover Yeztugo as a required preventive service, which means that PrEP users should not face any cost-sharing or utilization management barriers,” he said.
In response to a request by the Washington Blade for comment, a spokesperson for Gilead Sciences released a statement saying the annual list price per person using Yeztugo in the U.S. is $28,218. But the statement says the company is working to ensure that its HIV prevention medication is accessible to all who need it through broad coverage from health insurance companies and some of its own support programs.
“We’ve seen high insurance coverage for existing prevention options – for example, the vast majority of consumers have a $0 co-pay for Descovy for PrEP in the U.S. – and we are working to ensure broad coverage for lenacapavir [Yeztugo],” the statement says. It was referring to the earlier HIV prevention medication developed by Gilead Sciences, Descovy.
“Eligible insured people will get help with their copay,” the statement continues. “Gilead’s Advancing Access Copay Savings Program may reduce out-of-pocket costs to as little as zero dollars,” it says. “Then for people without insurance, lenacapavir may be available free of charge for those who are eligible, through Gilead’s Advancing Access Patient Assistance Program.”
Gilead Sciences has announced that in the two final trial tests for Yeztugo, which it describes as “the most intentionally inclusive HIV prevention clinical trial programs ever designed,” 99.9 percent of participants who received Yeztugo remained negative. Time magazine reports that among those who remained HIV negative at a rate of 100 percent were men who have sex with men.
Time also reports that some HIV/AIDS researchers believe the success of the HIV prevention drugs like Gilead’s Yeztugo could complicate the so-far unsuccessful efforts to develop an effective HIV vaccine.
To be able to test a potential vaccine two groups of test subjects must be used, one that receives the test vaccine and the other that receives a placebo with no drug in it.
With highly effective HIV prevention drugs now available, it could be ethically difficult to ask a test group to take a placebo and continue to be at risk for HIV, according to some researchers.
“This might take a bit of the wind out of the sails of vaccine research, because there is something so effective in preventing HIV infection,” Time quoted Dr. David Ho, a professor of microbiology, immunology, and medicine at New York’s Columbia University as saying.